Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Litton

Showing results (31-40 of 166) with videos related to

Pageof 17
Sort By:
Cancer|September 17, 2014
Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarianJacqueline Mersch, Michelle A Jackson, Minjeong Park, et al.
JNCI Cancer Spectrum|March 27, 2020
Prospective Evaluation of Universal <i>BRCA</i> Testing for Women With Triple-Negative Breast CancerTrisha S Emborgo, Donika Saporito, Kimberly I Muse, et al.
The Oncologist|August 21, 2012
The relationship between body composition and response to neoadjuvant chemotherapy in women with operable breast cancerEgidio Del Fabbro, Henrique Parsons, Carla L Warneke, et al.
Frontiers in Genetics|May 21, 2016
Evaluation of BRCAPRO Risk Assessment Model in Patients with Ductal Carcinoma In situ Who Underwent Clinical BRCA Genetic TestingNisreen Elsayegh, Angelica M Gutierrez Barrera, Kimberly I Muse, et al.
Cancer Medicine|May 8, 2018
Contralateral prophylactic mastectomy rate and predictive factors among patients with breast cancer who underwent multigene panel testing for hereditary cancerNisreen Elsayegh, Rachel D Webster, Angelica M Gutierrez Barrera, et al.
Familial Cancer|June 18, 2011
Communication of BRCA1 and BRCA2 genetic test results to health care providers following genetic testing at a tertiary care centerK Ready, B K Arun, K M Schmeler, et al.
Journal of Cancer|June 17, 2015
Predictors that Influence Election of Contralateral Prophylactic Mastectomy among Women with Ductal Carcinoma in Situ who are BRCA-NegativeNisreen Elsayegh, Jessica Profato, Angelica M Gutierrez Barrera, et al.
Oncotarget|May 15, 2015
Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?Fanny Le Du, Bedrich L Eckhardt, Bora Lim, et al.
Annals of Surgical Oncology|March 19, 2017
Results of a Phase Ib Trial of Combination Immunotherapy with a CD8+ T Cell Eliciting Vaccine and Trastuzumab in Breast Cancer PatientsG Travis Clifton, Jennifer K Litton, Karen Arrington, et al.
The Oncologist|August 19, 2018
Prognostic Factors in Patients with Metastatic Breast Cancer with Bone-Only MetastasesAmanda Parkes, Carla L Warneke, Katherine Clifton, et al.
Pageof 17

Showing results (31-40 of 166) with videos related to

Sort By:
Pageof 17
Cancer|September 17, 2014
Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarianJacqueline Mersch, Michelle A Jackson, Minjeong Park, et al.
JNCI Cancer Spectrum|March 27, 2020
Prospective Evaluation of Universal <i>BRCA</i> Testing for Women With Triple-Negative Breast CancerTrisha S Emborgo, Donika Saporito, Kimberly I Muse, et al.
The Oncologist|August 21, 2012
The relationship between body composition and response to neoadjuvant chemotherapy in women with operable breast cancerEgidio Del Fabbro, Henrique Parsons, Carla L Warneke, et al.
Frontiers in Genetics|May 21, 2016
Evaluation of BRCAPRO Risk Assessment Model in Patients with Ductal Carcinoma In situ Who Underwent Clinical BRCA Genetic TestingNisreen Elsayegh, Angelica M Gutierrez Barrera, Kimberly I Muse, et al.
Cancer Medicine|May 8, 2018
Contralateral prophylactic mastectomy rate and predictive factors among patients with breast cancer who underwent multigene panel testing for hereditary cancerNisreen Elsayegh, Rachel D Webster, Angelica M Gutierrez Barrera, et al.
Familial Cancer|June 18, 2011
Communication of BRCA1 and BRCA2 genetic test results to health care providers following genetic testing at a tertiary care centerK Ready, B K Arun, K M Schmeler, et al.
Journal of Cancer|June 17, 2015
Predictors that Influence Election of Contralateral Prophylactic Mastectomy among Women with Ductal Carcinoma in Situ who are BRCA-NegativeNisreen Elsayegh, Jessica Profato, Angelica M Gutierrez Barrera, et al.
Oncotarget|May 15, 2015
Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?Fanny Le Du, Bedrich L Eckhardt, Bora Lim, et al.
Annals of Surgical Oncology|March 19, 2017
Results of a Phase Ib Trial of Combination Immunotherapy with a CD8+ T Cell Eliciting Vaccine and Trastuzumab in Breast Cancer PatientsG Travis Clifton, Jennifer K Litton, Karen Arrington, et al.
The Oncologist|August 19, 2018
Prognostic Factors in Patients with Metastatic Breast Cancer with Bone-Only MetastasesAmanda Parkes, Carla L Warneke, Katherine Clifton, et al.
Pageof 17